Abstract

BackgroundThe area along the Thai-Cambodian border is considered an epicenter of anti-malarial drug resistance. Recently, parasite resistance to artemisinin-based therapies has been reported in the area. The artemisinin resistance containment project was initiated in November 2008, with the aim to limit resistant parasites and eliminate malaria in this region. This study describes the response to artemisinin-based therapy among falciparum malaria patients in the area, using data from the malaria surveillance programmed under the containment project.MethodsThe study was conducted in seven provinces of Thailand along the Thai-Cambodian border. Data of Plasmodium falciparum-positive patients during January 2009 to December 2011 were obtained from the electronic malaria information system (eMIS) Web-based reporting system. All P. falciparum cases were followed for 42 days, as the routine case follow-up protocol. The demographic characteristics of the patients were described. Statistical analysis was performed to determine the cure rate of the current standard anti-malarial drug regimen--mefloquine-artesunate combination therapy (MAS). The proportion of patients who remained parasite-positive at each follow-up day was calculated. In addition, factors related to the delayed parasite clearance on day-3 post-treatment, were explored.ResultsA total of 1,709 P. falciparum-positive cases were reported during the study period. Almost 70% of falciparum cases received MAS therapy (n = 1,174). The majority of cases were males, aged between 31 and 50 years. The overall MAS cure rate was >90% over the three-year period. Almost all patients were able to clear the parasite within 7 to 14 days post-treatment. Approximately 14% of patients undergoing MAS remained parasite-positive on day-3. Delayed parasite clearance was not significantly associated with patient gender, age, or citizenship. However, delayed parasite clearance varied across the study area.ConclusionAnti-malarial drug-resistant parasites should be closely monitored in the area along the Thai-Cambodian border. Although the MAS cure rate in this study area was above 90%, an increasing trend of treatment failure has been reported in neighboring parts. Effective malaria surveillance is an important component to monitor drug-resistance in the malaria containment project.

Highlights

  • The area along the Thai-Cambodian border is considered an epicenter of anti-malarial drug resistance

  • Anti-malarial drug-resistant parasites should be closely monitored in the area along the ThaiCambodian border

  • The mefloquine-artesunate combination therapy (MAS) cure rate in this study area was above 90%, an increasing trend of treatment failure has been reported in neighboring parts

Read more

Summary

Introduction

The area along the Thai-Cambodian border is considered an epicenter of anti-malarial drug resistance. Parasite resistance to artemisinin-based therapies has been reported in the area. This study describes the response to artemisinin-based therapy among falciparum malaria patients in the area, using data from the malaria surveillance programmed under the containment project. The effectiveness of artemisinin-based combination therapy has been acknowledged worldwide, contributing to a reduction in the global malaria burden, especially in areas where P. falciparum became highly resistant to chloroquine and sulphadoxinepyrimethamine [3]. Over the last five years, there has been increasing public health concern regarding the emergence of P. falciparum resistance to artemisinins along the Thai-Cambodian border, possibly spreading to other regions. The artemisinin-resistance situation remains critical in areas along the Thai-Cambodian border, where the incidence of falciparum infection has been declining drastically [7]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.